Trade
Bal Pharma share price
High risk
You have to be logged in to add this to Watchlist.- ₹101.30(-0.69%)July 8, 2025 14:44:11 PM IST
- NSE
- BSE
- Vol : 10.21K (NSE + BSE)Last 20 day avg : 29.68 K
Bal Pharma is trading -0.69% lower at Rs 101.30 as compared to its last closing price. Bal Pharma has been trading in the price range of 101.60 & 97.50. Bal Pharma has given -17.48% in this year & -0.31% in the last 5 days. Bal Pharma has TTM P/E ratio 18.48 as compared to the sector P/E of 23.19.The company posted a net profit of 5.43 Crores in its last quarter.Listed peers of Bal Pharma include Murae Organisor (-%), Krebs Biochemicals And Industr (-1.16%), Bal Pharma (-0.69%).The Mutual Fund holding in Bal Pharma was at -% in . The MF holding has - from the last quarter. The FII holding in Bal Pharma was at 0.14% in 31 Mar 2025. The FII holding has decreased from the last quarter.
- Overview
- Financials
- Forecast
- Technical Analysis
- Peers
- Shareholding
- About the company
- FAQ
Overview
Key Metrics
Updated on Jul 08, 2025, 09:04 PM UTC
- Dividend YieldHigher than industry1.16Annual dividends as a percentage of the stock price.
- P/BLower than historical values2.13The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
- P/ELower than historical values22.79Price-to-earnings ratio based on trailing 12-month earnings
- BetaLow volatility0.37Beta measures a stock's volatility compared to the overall market. A beta > 1 indicates higher volatility than the market.
- Debt To EquityHigher than industry1.94The debt-to-equity ratio, indicating a company's financial leverage.
- PEG Ratio-The PEG ratio evaluates a stock's valuation by comparing its P/E ratio to its earnings growth rate. A lower PEG suggests better value relative to growth
Price range
Day Range
|
| ||||
52 week range
|
| ||||
Bal Pharma News
Bal Pharma Financials
Financials
View allFinancials include key reports like the Profit & Loss Statement (P&L), Balance Sheet, and Cash Flow Statement, providing insights into a company's performance, financial health, and liquidity
- Income
- Balance Sheet
- Cash Flow
Loading...
Units in the chart are in crores
Insights
- Financial
- Valuation
Company is profitable
The company's revenue fell during March quarter by 13.47% from Rs 94.63 crore to Rs 81.88 crore, year-on-year- The company's profit declined by 0.72% year-on-year during the March quarter, dropping from Rs 5.47 crore to Rs 5.43 crore
- The debt to equity of the company is higher than the industry median
- Earnings are insufficient to cover the interest expenses on outstanding debt
Bal Pharma Technical Analysis
Pivot Level - classic
Key price levels (support and resistance) calculated using the previous day's high, low, and close, aiding in technical analysis and trading decisions
- R1
- 104.46
- R2
- 107.38
- R3
- 110.60
Pivot101.24
- S1
- 98.32
- S2
- 95.10
- S3
- 92.18
Short Term
Considers price movement over the last 1-2 weeks
Not Available
Long Term
Considers price movement over the last 6 months
Not Available
- Very Bearish
- Bearish
- Neutral
- Very Bullish
- Bullish
Trends unavailable at the moment.
Bal Pharma Peers
Return Comparison
Peers Comparison
Names | Technical rating | Price | %Change | Market Cap | P/E | P/B | Dividend Yield | Debt to Equity |
|---|---|---|---|---|---|---|---|---|
| Murae Organisor | Bullish | 0.97 | - | 180.32 | 25.50 | 0.91 | - | 102.06 |
| Krebs Biochemicals And Industr | Neutral | 85.00 | -1.16 | 183.28 | - | - | - | |
| Bal Pharma | Moderately Bullish | 101.30 | -0.69 | 161.27 | 22.72 | 2.13 | 1.16 | 40.58 |
| Auro Laboratories | Neutral | 253.55 | -0.57 | 154.98 | 86.14 | 3.69 | - | 77.00 |
| Bdh Industries | Bearish | 262.40 | 1.59 | 151.04 | 16.69 | 2.25 | 1.67 | - |
Bal Pharma Shareholding
View AllShareholding Pattern
Breakdown of a company's ownership structure, showing stakes held by Promoters, Mutual Funds, FII(s) & Others.
Shareholding pattern for Bal Pharma is currently unavailable
Please check back later.
Shareholding Insights
- Promoter(s) holds a high stake in the company at 50.86%
- Promoter(s) have decreased the stake in the company in last 12 months
- FIIs are invested in this company
- FIIs holding is constant over the last quarter at 0.14%
- Mutual Funds are not invested in this company.
Bal Pharma Corporate Actions
View all- Board Meetings
- AGM
- Dividends
- Bonus
- Split
- Rights
| Meeting Date | Purpose |
|---|---|
| 2025-05-29 | Audited Results & Dividend |
| 2025-02-13 | Quarterly Results & Fund Raising |
| 2024-11-14 | Quarterly Results |
| 2024-08-12 | Quarterly Results, ESOP & A.G.M. |
| 2024-05-28 | Audited Results & Final Dividend |
About the company Bal Pharma
- IndustryBiotechnology & Drugs
- ISININE083D01012
- BSE Code524824
- NSE CodeBALPHARMA
Bal Pharma Limited is a pharmaceutical company engaged in the manufacturing and selling of pharmaceutical products. The Company is engaged in the manufacturing and marketing of pharmaceutical formulations and active pharmaceutical ingredients (API). It specializes in prescription drugs, generic & OTC products, intravenous infusion, and bulk actives. The Company offers a range of APIs including antihistamine, platelet inhibitor, anti-diabetic, anticonvulsant, urinary incontinence, neuropathic pain, anti-allergy, anti-inflammatory, diuretic, acne treatment, and others. It also offers a range of formulations covering dosage forms-tablets, capsules, syrups, suspensions, IV infusions, ophthalmics, creams and ointments to various semi-regulated markets. The API products are being exported to Japan, Australia, Spain, the United Kingdom, Canada, Nigeria, Iceland, Slovenia, Romania, Brazil, Pakistan, Germany, South Africa, Serbia, Taiwan, Malaysia, Thailand, among others.
Bal Pharma Share Price FAQs
Bal Pharma is trading at 101.30 as on Tue Jul 08 2025 09:14:11. This is -0.69% lower as compared to its previous closing price of 102.00.
The market capitalization of Bal Pharma is 161.27 Cr as on Tue Jul 08 2025 09:14:11.
The 52 wk high for Bal Pharma is 157.90 whereas the 52 wk low is 76.30
Bal Pharma can be analyzed on the following key metrics -
- TTM P/E: 18.48
- Sector P/E: 23.19
- Dividend Yield: 1.19%
- D/E ratio: 1.94
Bal Pharma reported a net profit of 7.22 Cr in 2025.
Quick Links